ArticleBMC pediatrics2025
First reported case of de Novo claes-jensen syndrome (CJS) in Palestine: diagnostic challenges and genetic insights.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Individuals with reported and novel KDM5C variants present with seizures, a feature recapitulated in a Drosophila model.Human molecular genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClaes-Jensen syndrome (CJS) is a rare X-linked intellectual disability caused by mutations in the KDM5C gene, encoding a histone demethylase involved in chromatin remodeling and neurodevelopment. Males with hemizygous mutations in KDM5C present with intellectual disability, dysmorphism, and neurodevelopmental delays. Mutations, either maternally transmitted or de novo, account for 0.7-2.8% of X-linked intellectual impairments. This case reports a rare de novo variant in the KDM5C gene in a Palestinian male patient, contributing to the limited literature on this condition. CASE PRESENTATION: We present a 2-year and 10-month-old Palestinian male with developmental regression following an acute viral illness at 22 months. This included the loss of the ability to walk, developmental delays, and persistently elevated lactic acid. Genetic testing, including trio-based whole-exome sequencing, identified a de novo KDM5C mutation (c.2827 C > T p.Arg943), confirming the diagnosis of Claes-Jensen syndrome. Neuroimaging showed faint hyperintensities in the posterior periventricular white matter, suggestive of dysmyelination.
conclusionThis case highlights the diagnostic challenges of CJS and the importance of genetic testing in neurodevelopmental disorders. Early recognition aids in symptomatic management and improves clinical understanding of this rare condition. Our report adds new insight into the clinical spectrum of CJS and emphasizes the need for heightened awareness among clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.